Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients.
about
Circulating tumor DNA: a promising biomarker in the liquid biopsy of cancerCancer Evolution and the Limits of Predictability in Precision Cancer MedicineThe influence of subclonal resistance mutations on targeted cancer therapyMolecular Diagnostics for Precision Medicine in Colorectal Cancer: Current Status and Future PerspectiveClinical applications of liquid biopsies in gastrointestinal oncologyOncogenic fingerprint of epidermal growth factor receptor pathway and emerging epidermal growth factor receptor blockade resistance in colorectal cancerIdentification of Circulating Tumor DNA for the Early Detection of Small-cell Lung CancerToward understanding and exploiting tumor heterogeneityTranslating genomic profiling to gastrointestinal cancer treatment.Circulating Tumor Cells Versus Circulating Tumor DNA in Colorectal Cancer: Pros and Cons.Recent advances in preoperative management of esophageal adenocarcinomaRational design of non-resistant targeted cancer therapiesAnalysis of DNA Methylation Status in Bodily Fluids for Early Detection of CancerRecent Advances in Targeting the EGFR Signaling Pathway for the Treatment of Metastatic Colorectal CancerDetection of KRAS Exon 2 Mutations in Circulating Tumor Cells Isolated by the ISET System from Patients with RAS Wild Type Metastatic Colorectal CancerThe role of tumour heterogeneity and clonal cooperativity in metastasis, immune evasion and clinical outcomeA randomized phase 3 study on the optimization of the combination of bevacizumab with FOLFOX/OXXEL in the treatment of patients with metastatic colorectal cancer-OBELICS (Optimization of BEvacizumab scheduLIng within Chemotherapy Scheme).Improved Detection of Circulating Tumor Cells in Metastatic Colorectal Cancer by the Combination of the CellSearch® System and the AdnaTest®Use of liquid biopsies to monitor disease progression in a sarcoma patient: a case report.Treatment monitoring in metastatic colorectal cancer patients by quantification and KRAS genotyping of circulating cell-free DNA.Emerging concepts in liquid biopsiesCirculating tumor DNA changes for early monitoring of anti-PD1 immunotherapy: a proof-of-concept study.Development and validation of an ultra-deep next-generation sequencing assay for testing of plasma cell-free DNA from patients with advanced cancer.Precision oncology based on omics data: The NCT Heidelberg experience.Novel CAD-ALK gene rearrangement is drugable by entrectinib in colorectal cancerPathological responses after angiogenesis or EGFR inhibitors in metastatic colorectal cancer depend on the chemotherapy backboneHER2 genomic amplification in circulating tumor DNA from patients with cetuximab-resistant colorectal cancer.Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients.Identification of Targetable Kinase Alterations in Patients with Colorectal Carcinoma That are Preferentially Associated with Wild-Type RAS/RAFAnalysis of ESR1 mutation in circulating tumor DNA demonstrates evolution during therapy for metastatic breast cancer.Mutation analysis of circulating plasma DNA to determine response to EGFR tyrosine kinase inhibitor therapy of lung adenocarcinoma patientsctDNA dynamics: a novel indicator to track resistance in metastatic breast cancer treated with anti-HER2 therapyLoss of AXIN1 drives acquired resistance to WNT pathway blockade in colorectal cancer cells carrying RSPO3 fusionsA module of inflammatory cytokines defines resistance of colorectal cancer to EGFR inhibitors.Gankyrin sustains PI3K/GSK-3β/β-catenin signal activation and promotes colorectal cancer aggressiveness and progression.HER-2 inhibition in gastric and colorectal cancers: tangible achievements, novel acquisitions and future perspectives.The implication of FLT3 amplification for FLT targeted therapeutics in solid tumors.Tumor Heterogeneity and Lesion-Specific Response to Targeted Therapy in Colorectal Cancer.Mutation-Enrichment Next-Generation Sequencing for Quantitative Detection of KRAS Mutations in Urine Cell-Free DNA from Patients with Advanced Cancers.Anti-EGFR monoclonal antibody panitumumab for the treatment of patients with metastatic colorectal cancer: an overview of current practice and future perspectives.
P2860
Q26746010-2C3B56BF-960F-4B35-8F58-0BC36C7DC9FFQ26767415-3BF924F1-7CB1-4CFE-BCA4-827005CA9617Q26781693-6D403A3E-4214-4625-8612-8D4DC20E8C3CQ28070038-B5DD9EC3-36A1-4828-9469-DE43D6FB5772Q28073730-4447CA6E-BCAF-43E5-90C7-82E22D5713E5Q28077545-A5A4D30D-78A8-450D-A753-72FDFD11A5FBQ28390093-BE8A257F-1B96-45ED-905B-3B9C7047DCADQ28603034-16F7EE60-2D6F-4255-B7A1-B1A25065CEF0Q30239109-F6AC42EC-84CE-46CB-AC27-E41AF8EE2FCAQ30355079-0C109922-F1E7-4712-B1F1-B664F363CB55Q33589301-E02A255B-424C-4D45-9C0F-3FC0FDEB4D6FQ33594692-02801E18-37FC-40B5-8FF1-C84C33C3CBF8Q33624423-4257B8F4-218B-4902-B58F-4E3363FF39FEQ33624491-80F4F896-343C-44B5-AE82-D9C09346F7CCQ33889715-A9597686-7BDB-4138-8183-B97E2636804DQ33913152-48DB1FB9-A0EA-42D1-827A-674CF937A8AAQ35917810-580C6971-020D-424A-B370-874845B325E9Q36018511-B9DD03C3-05CD-462B-B689-E9CA1783C986Q36243135-9F24126B-B7CF-4CE0-9F3E-4733EB87E3C2Q36318273-823348AA-0DE6-4DC4-8DA0-BE19B040C371Q36337259-9FA792FB-8170-431B-93ED-3D878F49D2AFQ36359821-06BCC608-2765-4C8C-94D4-DE03F40A24D3Q36378903-5F9D9A2A-9A36-4FD5-97E4-46E5D7FBA87DQ36396606-7BEB35F0-F6B5-4C23-8589-1EB228ABFEF0Q36432094-490C8A75-8487-47EA-9FAA-99BFCA54184EQ36750646-620C9EDD-F63D-43BE-BCC5-70B8F0B16197Q36772167-256560C1-831D-4E6C-9A16-2DDE985AEF17Q37000646-365526EC-E742-4901-9EF5-57D8F1F526C9Q37149773-1BAF7A45-31D8-4D76-9CB1-8F56C19F3028Q37206520-0107BD36-D480-483E-A78D-237E0F370BDFQ37264652-12B0403D-DA11-414D-8018-59998329C0EBQ37662351-3C343894-D60C-4363-9BDD-9709DE65CE6FQ37672680-6FEB6B59-A184-49E6-B8B3-4A11A2903E8FQ37687796-B9539F2D-E13B-4708-B713-1661DCC2841FQ37697139-EF659AAB-21E3-4835-BB10-1A8C4969EE6BQ37708897-52FF9FA6-DB3C-4525-B0B8-58D47A1FAFB3Q37709456-1702DD25-D468-4129-A80D-547A1A679300Q38275060-249B6BEB-5177-4B33-A917-690CF5D5F0F8Q38376337-CFBF2F77-1ED7-4571-8C3D-E638AED50B9DQ38650454-FFA926A5-4404-4287-91CA-DF4AC7087B79
P2860
Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
Clonal evolution and resistanc ...... of colorectal cancer patients.
@en
Clonal evolution and resistanc ...... of colorectal cancer patients.
@nl
type
label
Clonal evolution and resistanc ...... of colorectal cancer patients.
@en
Clonal evolution and resistanc ...... of colorectal cancer patients.
@nl
prefLabel
Clonal evolution and resistanc ...... of colorectal cancer patients.
@en
Clonal evolution and resistanc ...... of colorectal cancer patients.
@nl
P2093
P2860
P50
P356
P1433
P1476
Clonal evolution and resistanc ...... of colorectal cancer patients
@en
P2093
Agostino Ponzetti
Andrea Cassingena
Beatriz Bellosillo
Calogero Lauricella
Carlotta Antoniotti
Chiara Cremolini
Clara Montagut
Michela Buscarino
Patrizia Racca
Ryan B Corcoran
P2507
P2860
P2888
P304
P356
10.1038/NM.3870
P407
P50
P577
2015-06-01T00:00:00Z